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Abstract
Dolutegravir is a second generation integrase strand transfer inhibitor (INSTI) currently under
review by the US FDA for marketing approval. Dolutegravir’s in vitro, protein adjusted 90%
inhibitory concentration (IC90) for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1
activity across a broad range of viral phenotypes known to confer resistance to the currently
marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a half-life (t½) of 13 to 14 hours
and maintains concentrations over the in vitro, protein adjusted IC90 for more than 30 hours
following a single dose. Additionally, dolutegravir has comparatively low intersubject variability
compared to raltegravir and elvitegravir. A plasma exposure-response relationship has been well
described, with antiviral activity strongly correlating to trough concentration (Ctrough) values.
Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and
raltegravir in antiretroviral (ARV)-naïve patients and found dolutegravir to achieve more rapid
and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity
in patients with known INSTI-resistant mutations have been favorable, indicating that dolutegravir
retains activity in a variety of INSTI resistant phenotypes. Much like currently marketed INSTIs,
dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter, organic
cation transporter (OCT) 2, reduced tubular secretion of creatinine leads to non-progressive
increases in serum creatinine. These serum creatinine increases have not been associated with
decreased glomerular filtration rate or progressive renal impairment. Dolutegravir’s major and
minor metabolic pathways are UDP glucuronosyltransferase (UGT)1A1 and cytochrome
(CYP)3A4, respectively, and it neither induces nor inhibits CYP isozymes. Thus dolutegravir has
a modest drug interaction profile. However, antacids significantly decrease dolutegravir plasma
exposure and should be separated by 2 hours before, or 6 hours after, a dolutegravir dose. In
summary, dolutegravir is the first of the second generation INSTIs, which exhibits a predictable
pharmacokinetic profile and a well-defined exposure-response relationship. Dolutegravir retains
activity despite the presence of some class resistant mutations and achieves rapid and sustained
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virologic suppression in ARV-naïve and -experienced patients. Clinically dolutegravir is poised to
become a commonly used component of antiretroviral regimens.
1. Introduction
The well-tolerated integrase strand transfer inhibitors (INSTIs) are the newest class of
antiretrovirals (ARVs), demonstrating potent anti-HIV activity through inhibition of the
enzyme responsible for incorporating viral DNA into the host genome [1]. Two currently
marketed INSTIs include raltegravir (MSD, Whitehouse Station, NJ, USA) and elvitegravir
(Gilead Sciences, Foster City, CA, USA). Raltegravir was approved by the US FDA for
market in 2007. Stribild (Gilead Sciences, Foster City, CA, USA), a combination tablet
containing elvitegravir, was approved in 2012. Despite their comparatively short period of
clinical use and a high genetic barrier to resistance, resistant phenotypes have been reported
for both [2–5]. Certain mutations, such as Q148H/R, N155H, and Y143R confer cross-
resistance between raltegravir and elvitegravir [5], and further necessitate the development
of second generation INSTIs.
Dolutegravir, a novel INSTI currently under review by the US FDA for marketing approval,
is a chiral, non-racemic compound with a molecular weight of 419 g/mol (Figure 1).
Dolutegravir fits loosely into the intasome binding pocket and retains its binding ability
despite conformational changes in the pocket structure [6]. The ability to readjust its binding
position is believed to enhance the genetic barrier to ARV resistance, subsequently
classifying dolutegravir as a second generation INSTI.
Dolutegravir is highly potent, with an in vitro half maximal inhibitory concentration (IC50)
of 2.7nM and an in vitro half maximal effective concentration (EC50) against HIV-1 of 0.51
nM in peripheral blood mononuclear cells [7] (Raltegravir and elvitegravir have an in vitro
IC50 of 3.3nM and 6nM respectively). Dolutegravir dissociates more slowly than raltegravir
and elvitegravir from integrase-DNA complexes with mean koff (s−1 × 10−6) values of 2.7,
22 and 71, respectively for wild-type complexes, and 37, 1160, and 1130 from complexes
expressing a single Q148H mutation [8]. Multiple in vitro studies utilizing a large variety of
viral phenotypes no longer susceptible to raltegravir demonstrate retained dolutegravir
activity [7,9,10]. However, mutations at the 148 position of integrase did impart diminished
in vitro dolutegravir susceptibility with median in vitro IC50 fold changes ranging from 3.01
to 27.12 compared to wild-type virus depending on the type and number of secondary
mutations [9,10]. These preclinical findings suggest dolutegravir would retain some antiviral
activity in individuals previously exposed to raltegravir therapy.
2. Pharmacokinetics
The dolutegravir pharmacokinetic profile under single dose and steady state conditions
ranging from 2 to 100 mg per day has been assessed in healthy and HIV infected adults
[11,12]. Dolutegravir exhibits rapid absorption, with a median time to maximum
concentration (tmax) ranging from 0.5 to 2 hours. Dolutegravir also displays extensive
protein binding with >99% of the dolutegravir blood plasma concentrations bound to
albumin and alpha 1-acid glycoprotein (AAG) [7,13]. The terminal elimination half-life (t½)
of dolutegravir was 13 to 14 hours in healthy subjects and 11 to 12 hours in HIV infected
subjects. Single doses of 5, 10, 25, 50 and 100 mg achieved plasma dolutegravir
concentrations greater than the in vitro, protein-adjusted IC90 of 0.064 μg/ml for more than
30 hours following oral administration. Multiple daily doses ranging from 10 to 50 mg in
both uninfected and infected subjects yielded trough plasma concentrations (Ctrough) 3–25
times greater than this in vitro threshold (Table 1) [11,12]. Dolutegravir exhibits lower inter-
subject pharmacokinetic variability than other integrase inhibitors. Dolutegravir’s
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coefficients of variation (CV) are <30% for both AUC and Cmax in single and multiple dose
studies, whereas raltegravir and elvitegravir demonstrate AUC CVs of 212% and 33–72%,
respectively [1,14].
Reese et. al. extensively characterized the metabolism and transport of dolutegravir using in
vitro model systems [15]. Dolutegravir is primarily metabolized by UGT1A1, and is only a
minor substrate for CYP3A4. Dolutegravir inhibited CYP3A4 but not 1A2, 2A6, 2B6, 2C8,
2C9, 2C19, or 2D6 in pooled human liver microsomes. Furthermore, at clinically relevant
concentrations neither inhibition nor induction of the aforementioned CYP enzymes or
UGT1A1/2B7 is observed. Dolutegravir is a substrate for the transporters, P-glycoprotein
(Pgp) and breast cancer resistance protein (BCRP), but does not demonstrate inhibition or
induction of the transporters Pgp, BCRP, organic anion transporter (OAT)P1B1, OATP1B3,
multidrug resistance protein (MRP)2 or organic cation transporter (OCT)1 at clinically
relevant concentrations. Dolutegravir does potently inhibit the renal transporter OCT2 at
concentrations which are below peak concentrations demonstrated in clinical trials (in vitro
IC50= 1.9 μM, dolutegravir Cmax=7.97–14.7 μM).
While not believed to be clinically important, dolutegravir absorption is modestly affected
by fat content of a meal. Song et. al. observed an increase of 133 to 242% in AUC∞, Cmax,
and tmax following a single 50 mg dose under fasted conditions compared to a low,
moderate, and high fat meal [16]. Favorably, food decreases inter-subject pharmacokinetic
variability with a median CV of 27.5% for all pharmacokinetic parameters. Phase 2 and 3
investigations to date have not employed food restrictions for dolutegravir dosing [17–19].
As discussed below, these clinical trials demonstrate good dolutegravir efficacy and
tolerability.
Although dolutegravir’s pathways of metabolism and transport may indicate that
dolutegravir is relatively unaffected by population diversity, there are currently no studies
conducted that have specifically assessed the effects of demographic diversity on
dolutegravir pharmacokinetic parameters. Further investigations evaluating the effect of sex
and race on dolutegravir pharmacokinetics are warranted, as studies to date have primarily
enrolled White men between the ages of 19–54 years and BMI of 20.9–29.1mg/m2 [11],
leaving some portions of the HIV infected population underrepresented.
Dolutegravir exposure has been studied in secondary body compartments including the
central nervous system, the female genital tract, the male genital tract, and colorectal tissue
[20,21]. Letendre et. al. investigated the pharmacokinetics of dolutegravir in the
cerebrospinal fluid (CSF) of 12 ARV-naïve, HIV infected subjects receiving 50 mg
dolutegravir daily with an abacavir/lamivudine backbone regimen [20]. Distribution to the
CSF was similar to the unbound dolutegravir fraction in blood plasma at Week 2 (mean CSF
dolutegravir= 16.2 ng/ml, mean plasma unbound dolutegravir =16.8 ng/ml) and at Week 16
(mean CSF dolutegravir = 12.6 ng/ml, mean plasma unbound dolutegravir=23 ng/ml).
Additionally dolutegravir exposure in the CSF for all subjects at Week 16 ranged from 18 to
90 fold higher than the in vitro IC50 for wild type virus (0.2ng/ml) [20]. These findings
suggest free passage of the small molecule across the blood brain barrier.
After single and multiple dosing, dolutegravir exposure in cervicovaginal fluid (CVF),
cervical tissue and vaginal tissue was 5–7% of blood plasma exposure. This is in contrast to
raltegravir, that achieves ~200% of blood plasma exposure in CVF [22]. Despite this
relatively low penetration, within 4–5 hours after a single dose, the CVF exposure is above
the in vitro, protein adjusted IC90. Similar to what has been previously identified for
maraviroc [23], since concentrations of the major drug-binding proteins (AAG and albumin)
are less than 10% of blood plasma concentrations in the CVF [24], it may be that a larger
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proportion of this CVF concentration is available as protein-unbound (e.g.
pharmacologically active) drug. In semen, dolutegravir concentrations are 6–7% blood
plasma concentrations. This is strikingly different from raltegravir, which achieves seminal
plasma concentrations that are 425–645% blood plasma concentrations [25,26]. Like CVF,
albumin concentrations in seminal plasma are less than 10% of blood plasma concentrations
[27]. Therefore, although not directly measured, it is possible that a larger proportion of the
dolutegravir seminal plasma concentration is pharmacologically active [21]. Distribution to
colorectal tissue was rapid and sustained with 100% of subjects achieving detectable
dolutegravir concentrations within one hour of a single dose that remained above the in
vitro, protein adjusted IC90 for the duration of the dosing interval [21]. Overall, dolutegravir
exposure was ~18% of plasma concentrations.
2.1 Special populations
Only a small proportion of dolutegravir dose (< 1%) is excreted unchanged in the urine; and
therefore, dolutegravir is not expected to require dose adjustments with renal impairment
[11]. The results of an open label, single dose clinical trial evaluating dolutegravir’s
pharmacokinetic profile in 16 subjects with normal or impaired renal function (creatinine
clearearence <30ml/min) are currently being evaluated [28]. Initial reports indicate that
following a 50 mg single dose dolutegravir AUC∞ and Cmax are reduced by 40% and 23%
respectively, which is considered clinically insignificant [29]. One adverse event (dizziness)
was reported in the renally impaired group, and 2 (nasal congestion and hemotoma) were
reported in the healthy group. Currently no dosage adjustments are recommended for
dolutegravir in patients with renal impairment.
Dolutegravir is extensively metabolized in the liver by UGT1A1 [11]. Preliminary study of a
single 50 mg dolutegravir dose in a cohort of subjects with moderate hepatic impairment
(Child-Pugh score 7–9) revealed that, overall, dolutegravir plasma exposure is unchanged
and well tolerated in mild to moderate hepatic impairment [13]. However, it was noted that
the unbound fraction of dolutegravir in plasma is higher in hepatically impaired subjects
than in healthy volunteers (0.41% vs 0.23%). Further investigation is warranted to assess the
tolerability of multiple dolutegravir doses in patients with hepatic impairment.
A large clinical trial evaluating the pharmacokinetic profile and immune response to
dolutegravir in infants and adolescents 6 weeks to 18 years of age is currently underway
[30]. Preliminary steady state pharmacokinetic data have been reported for 10 adolescent
females with a mean age (SD) of 14 years (1.89) [31]. Following a weight based, fixed dose
of approximately 1 mg/kg the dolutegravir AUC24 (CV) and Ctrough (CV) were 46mg•hr/ml
(43%) and 0.9mg/ml (58%) respectively. These fell within pre-defined target
pharmacokinetic exposure ranges for both AUC24 (37–67 mg•h/ml) and Ctrough (0.77–2.26
mg/ml). Furthermore, this exposure was similar to the exposure demonstrated in adult
pharmacokinetic studies following a daily 50 mg dose (Table 1). However, higher inter-
subject variability was seen in adolescents than adults. Dolutegravir and an optimized
backbone regimen were well tolerated with no adverse events leading to discontinuation of
study drug.
3. Pharmacodynamics
In 35 ARV-naïve subjects, 10 days of monotherapy was investigated for dolutegravir doses
of 2mg, 10mg, and 50mg daily. These doses resulted in a mean ±SD reduction of plasma
HIV-1 RNA of −1.51±0.58, −2.03±0.49, and −2.46±0.35 (log10 copies/ml), respectively
(Figure 2) [12]. Dolutegravir doses of 10 and 50 mg once daily yield Ctrough values that
were ~3 and 13 times higher than the in vitro, protein adjusted IC90 (0.064 μg/ml). Increased
dolutegravir plasma exposure was correlated with reduced plasma HIV-1 RNA. Both log-
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linear and sigmoid Emax models were evaluated to describe the pharmacokinetic-
pharmacodynamic relationship of the compound. Dolutegravir’s exposure-response
relationship was best described by a sigmoid Emax model utilizing the pharmacokinetic
parameters, Day 10 AUC24, Cmax and Cτ, with Emax fixed at −2.6 and Hill factor fixed to
1[32]. The in vivo EC50 demonstrated by this Emax model was 0.036 μg/ml. The model
identified Ctrough as the pharmacokinetic parameter which best-predicted plasma viral load
reduction on Day 11 of monotherapy [12]. Additionally, the inhibitory quotient (IQ),
calculated by Ctrough÷protein adjusted IC90, was also identified as a predictor of virologic
response. Based on these data, phase 2 studies investigated daily doses of 10–50mg.
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered with Either
Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy
Naive Adult Subjects (SPRING-1) [17] assessed daily dolutegravir 10 mg, 25 mg, and 50
mg compared to the active control efavirenz 600 mg in ARV-naïve subjects. All regimens
contained a nucleoside reverse transcriptase inhibitor (NRTI) backbone of lamivudine plus
abacavir or tenofovir disoproxil fumarate plus emtricitabine. Analysis at 48-weeks
demonstrated more rapid and sustained virologic suppression, defined as HIV RNA <50
copies/ml, for all dolutegravir dosing arms compared with the efavirenz control group
(Figure 3) [17]. The proportion of subjects achieving virologic suppression in each
dolutegravir dosing arm ranged from 90–96% and 88–91% at 16 and 48 weeks respectively.
No significant difference in efficacy was observed among the dolutegravir dosing arms.
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once
Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual
Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected
Antiretroviral Therapy Naive Adult Subjects (SPRING-2) [19], a phase 3 non-inferiority
trial, assessed the efficacy of once daily 50 mg dolutegravir against twice daily 400 mg
raltegravir as first line treatment with dual-NRTI backbone therapy in ARV-naïve subjects.
Four hundred and eleven subjects were enrolled into each of the two blinded and masked
treatment arms and followed for 48 weeks. The primary endpoint of SPRING-2 was the
proportion of subjects achieving a viral load of <50 copies/ml at 48 weeks of therapy. The
pre-specified non-inferiority criterion was a lower 95% CI bound for the difference in
proportion of patients meeting primary endpoints (dolutegravir minus raltegravir) of greater
than −10%. Dolutegravir was found to be non-inferior to raltegravir with a difference of
2.5% (95% CI −2.2% to 7.1%) [19]. Consistent with findings from the SPRING-1 trial,
dolutegravir demonstrated slightly more rapid and sustained virologic suppression when
compared with raltegravir (Figure 3). The more rapid rate of viral attenuation seen with
dolutegravir may warrant consideration of this agent in clinical scenarios requiring rapid
virologic suppression such as HIV-infected patients presenting with AIDS defining illness or
women presenting late in pregnancy. Across most treatment arms, the proportion of
virologic non-responders in SPRING-1 and −2 trials was 0–3% higher between efavirenz
and raltegravir-treated groups [17,19]. No treatment emergent INSTI resistance was
identified among the dolutegravir treatment arms of SPRING-1 and -2.
The phase 3, non-inferiority trial, A Randomized, Double-Blind Study of the Safety and
Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy
Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected
Antiretroviral Therapy Naive Adult Subjects (SINGLE), evaluated the efficacy of
dolutegravir 50 mg once daily with an abacavir/lamivudine backbone regimen compared
with efavirenz/tenofovir disoproxil fumarate/emtricitabine once daily in 833 subjects [33].
The dolutegravir arm demonstrated statistical superiority to efavirenz/tenofovir disoproxil
fumarate/emtricitabine for the primary endpoint, with a difference in proportion of subjects
with HIV RNA <50 copies/ml at 48 weeks of +7.4% (95% CI: 2.5% to 12.3%; p=0.003)
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favoring the dolutegravir arm (Figure 3). Additionally, the median time to HIV RNA
suppression in the dolutegravir group was −56 days compared to the efavirenz group
(p<0.001). A subgroup analysis of the SPRING-2 and SINGLE studies investigated the
efficacy of dolutegravir in subpopulations stratified by baseline viral load, CD4 count, sex,
age, and race. Dolutegravir demonstrated equivalent efficacy in all demographic subgroups
for both phase 3 trials [34].
To assess whether dolutegravir retained activity in the face of ARV resistance, A Pilot Study
to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral
Therapy (ART)-Experienced, HIV-1-infected Adult Subjects with Raltegravir Resistance
(VIKING) enrolled 51 subjects with documented INSTI resistance and resistance to at least
1 additional agent into 2 treatment cohorts [18]. The VIKING treatment plan consisted of
adding dolutegravir to a failing backbone regimen for 10 days before optimizing the
backbone regimen. Cohort I received dolutegravir 50 mg once daily and cohort II received
50 mg twice daily. A higher proportion of patients in cohort II met the definition of response
at day 11 (HIV RNA ≥0.7 log10 copies/ml decrease or <400 copies/ml) and week 24 (HIV
RNA <50 copies/ml) than in cohort I (Figure 3). Therefore, in the presence of INSTI
resistance, a higher dose of dolutegravir may be warranted.
The single arm, Phase III Study to Demonstrate the Antiviral Activity and Safety of
Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase
Inhibitor Containing Regimen (VIKING-3) [35], was designed to evaluate the efficacy of
dolutegravir 50 mg twice daily in subjects with INSTI resistant virus plus resistance to at
least 2 other ARV classes. Dolutegravir was added to the failing backbone regimen for 8
days before the regimen was optimized. Interim analysis from VIKING-3 demonstrated that,
despite high levels of ARV resistance, 63% of the 72 evaluable subjects had viral loads of
<50 copies/ml at 24 weeks [35]. These findings are consistent with preclinical work
demonstrating dolutegravir’s activity against raltegravir resistant virus. The VIKING studies
provide encouraging data supporting the option of using dolutegravir 50 mg twice daily in
salvage regimens.
In the first VIKING trial, treatment emergent genotypic resistance was observed in 4/12 and
3/5 subjects experiencing virologic failure in Cohort I and II respectively [18]. All subjects
experiencing treatment emergent resistance also exhibited baseline INSTI resistant
mutations. In both Cohorts, the presence of Q184H+G140S with additional raltegravir
resistant mutations was associated with decreased virologic response to dolutegravir
treatment. Similarly, subjects in the VIKING-3 trial with 2 or more primary mutations or a
mutation of the Q148 pathway (Q148H/K/R) at baseline were more likely to experience
virologic failure [35]. Only 69% of subjects with Q148H/K/R mutation and ≤ 1 secondary
mutations and 48% of those with a Q148H/K/R and ≥ 2 secondary mutations met the
definition of virologic response (>1 log HIV RNA decline or <50 copies/ml) at day 8.
A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once
Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-
selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve,
Antiretroviral-Experienced Adults (SAILING) is an ongoing, phase 3, non-inferiority
investigation of the efficacy of 50 mg dolutegravir once daily in ARV-experienced, INSTI-
naive patients compared to 400 mg raltegravir twice daily [36]. A 24-week interim analysis
of the SAILING trial demonstrated an adjusted difference in proportion of subjects with
viral loads <50 copies/ml of +9.7% (95% CI +3.1%, 15.9%) in favor of the dolutegravir
treatment group (p=0.003). These preliminary findings further demonstrate that dolutegravir
will likely be an effective option in ARV-experienced subjects.
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Dolutegravir demonstrated a favorable safety profile in phase 2 and 3 trials. Dolutegravir
was better tolerated than efavirenz with only 2 (1%) adverse events leading to subject
withdrawal in the dolutegravir arm compared with 4 (8%) in the efavirenz arm of SPRING-1
[17]. Of the two adverse events leading to subject withdrawal from a dolutegravir dosing
arm, only 1 (grade 2 dyspesia) was deemed related to study drug, while all 4 of the adverse
events were related to efavirenz treatment. Similarly 10 subjects (2%) in the SINGLE trial
withdrew from the dolutegravir arm secondary to adverse events compared with 42 (10%)
from the efavirenz arm [33]. Dolutegravir and raltegravir were similarly tolerated with
adverse event related dropout rates of 2% in each arm of the SPRING-2 trial [19].
Table 2 provides a summary of adverse events reported by SPRING-1 and -2, SINGLE and
VIKING. The majority of patients in each clinical trial experienced some adverse event
during the course of treatment with adverse event rates ranging from 57–89%. Nausea,
headache, diarrhea, and sleep disturbances were among the most commonly reported
adverse events being reported in 5–23% of subjects. No dose related patterns were identified
for any type or frequency of adverse events reported in the dose ranging SPRING-1 trial.
The majority of treatment-emergent adverse events were mild or moderate in nature with
5%, 7% and 14% of subjects in dolutegravir treatment arms reporting any serious adverse
events in the SPRING-1, -2 and the first VIKING trial respectively [17,18]. Additionally, no
serious study drug-related adverse events were reported for the dolutegravir treatment arm
of the SPRING-1 or the VIKING trial. Three (<1%) study drug-related serious adverse
events were reported for the dolutegravir arm of SPRING-2: arrhythmia, hepatitis, and
hypersensitivity [19]. One (<1%), hypersensitivity reaction was reported for the dolutegravir
arm of the SINGLE trial [33]. In the efavirenz arm of the SPRING-1 and SINGLE trials, 1
(2%) and 8 (2%) subjects, respectively, reported study drug-related serious adverse events (1
suicide attempt, 4 psychiatric adverse events, 2 hypersensitivity, 1 cerebral vascular accident
and 1 renal failure) [17,33]. For the raltegravir arm of the SPRING-2 trial, 5 (1%) study
drug-related serious adverse events were reported (aphasia, convulsion, diarrhea,
hypersensitivity and increased CPK) [19].
The frequencies of graded laboratory abnormalities reported for the SPRING-1, -2, and
SINGLE were similar between all dolutegravir treatment and comparator arms. Laboratory
abnormalities reported in 1–5% of subjects included increased cholesterol, lipase, bilirubin,
AST/ALT, CPK and prothrombin time as well as decreased phosphorous and neutrophil
count [17,19,33]. Early investigation in SPRING-1, -2 and VIKING revealed a modest, non-
progressive increase in serum creatinine associated with all dolutegravir dosing groups and
cohorts which was apparent after approximately one week of therapy and remained stable
through 24 weeks [17–19]. Subsequent iohexol plasma clearance investigations revealed that
glomerular filtration rate (GFR) is not affected by dolutegravir [38]. Thus, this observation
is likely due to dolutegravir -mediated inhibition of renal OCT2 transporter activity, with
reduced tubular secretion of creatinine [15]. Dolutegravir use over 48 weeks of therapy does
not appear to impact renal function [17,19] although the long-term effects of dolutegravir on
renal function are still unknown.
A supratherapeutic dose of dolutegravir (250 mg once) demonstrated maximal prolongation
of the QT interval of 1.99 msec (90% CI −0.55 to 4.53 msec) at 4 hours post dose [39]. Yet,
this change was not considered clinically relevant when compared with the QT prolongation
of 9.58 msec (90% CI 7.05–12.1) demonstrated by a single 400mg dose of moxifloxacin as a
positive control. Much like first generation INSTIs, dolutegravir’s side effect profile may
make the compound a reasonable alternative in patients who are unable to tolerate the
central nervous system or gastrointestinal side effects of efavirenz and protease inhibitors
(PIs), respectively.
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More than 20 drugs (Table 3) have been assessed for potential drug interactions with
dolutegravir. These include ARVs likely to be used in combination therapy, such as NRTIs,
non-nucleoside reverse transcriptase inhibitors (NNRTIs), and PIs. In addition, studies
evaluating the drug interactions between dolutegravir and acid-reducing agents,
multivitamins (MVI), oral hormonal contraceptives (OCs), antimycobacterial agents and
direct-acting agents for hepatitis C virus (HCV), have been conducted.
4.1 CYP3A probe substrates
As previously discussed in this review, in vitro studies have demonstrated low potential for
dolutegravir -mediated drug interactions by demonstrating that dolutegravir does not induce
or inhibit CYP or UGT isoenzymes at clinically relevant concentrations [15]. To confirm
these CYP3A findings in vivo, the drug interaction potential of dolutegravir has been
examined in a sub study of 10 healthy volunteers receiving dolutegravir 25 mg daily for 10
days and a single dose of 3 mg oral midazolam syrup on day 10. The pharmacokinetic effect
of dolutegravir on midazolam was compared to subjects receiving placebo with midazolam
(n=2). Plasma midazolam exposure was unchanged by dolutegravir (dolutegravir AUC=15.4
ng•h/ml vs placebo AUC=16.3 ng•h/ml) demonstrating that dolutegravir does not induce or
inhibit CYP3A [11]. Thus, dolutegravir mediated drug interactions with CYP3A substrates
are unlikely.
4.2 Nucleoside(tide) Reverse Transcriptase Inhibitors
Because NRTIs do not undergo hepatic transformation via the CYP metabolic pathway, drug
interactions are not as common with this class compared to NNRTIs and PIs [40]. Thus,
drug interaction potential with NRTIs and dolutegravir is low. No clinical studies have
quantified the interaction between dolutegravir and commonly used NRTIs such as
emtricitabine, abacavir, or lamivudine. However, as discussed previously, phase II/III
clinical trials [19,33] have successfully used dolutegravir in combination with these NRTIs
without dose adjustments.
Although the mechanistic drivers of tenofovir-mediated drug interactions are not well
understood, tenofovir is known to reduce atazanavir exposure possibly through induction of
CYP or UGT metabolic pathways. For this reason, an open-label, repeat-dose study was
conducted to assess the effects of concomitant dolutegravir and tenofovir disoproxil
fumarate [41]. Fifteen healthy volunteers received 5 days of daily 50 mg dolutegravir,
followed by a washout period of 6 days. Tenofovir disoproxil fumarate 300 mg daily was
then administered for 7 days before daily dolutegravir 50 mg was added for an additional 5
days. The pharmacokinetic parameters of dolutegravir and tenofovir, assessed on the last
day of each treatment period, demonstrated no clinically significant drug interaction [41].
4.3 Non-nucleoside reverse transcriptase inhibitors
Efavirenz exhibits a complicated interaction profile. It is primarily a substrate of CYP2B6
and an inducer of UGT1A1 as well as a mixed inducer/inhibitor of CYP3A4 [40, 42]. Since
efavirenz has the potential to induce both the major and minor metabolic pathways of
dolutegravir, reduced dolutegravir plasma concentrations would be expected if co-
administered. The effects of efavirenz on dolutegravir pharmacokinetics have been
evaluated in healthy subjects [43,44]. A total of 12 volunteers received 50 mg of
dolutegravir once daily for 5 days, then dolutegravir plus 600 mg of efavirenz once daily for
14 days. Co-administration with efavirenz reduced the dolutegravir AUC and Cmax by 57%
and 39% respectively. However, the dolutegravir trough concentrations demonstrated a 75%
reduction with a mean Ctrough of 0.22 μg/ml when co-administered with efavirenz. Although
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Ctrough values remained above the in vitro, protein adjusted IC90, they did fall below the in
vivo EC90 (0.324 μg/ml) calculated from the Emax model discussed above [32,43,44].
Despite this reduction, the mean Ctrough was similar to trough concentrations in the 10 mg
dolutegravir treatment arm of the SPRING-1 trial (0.3 μg/ml), which demonstrated similar
efficacy as the 50mg daily dosing arm [17]. Therefore, no dose adjustments are currently
recommended when co-administering dolutegravir and efavirenz in INSTI-naive patients.
However, careful clinical consideration should be given to individual patients. For those that
may require more forgiveness for missed doses, or who may have increases in HIV RNA
documented during careful virologic monitoring, using dolutegravir 50mg twice daily may
be considered.
To investigate the drug interaction potential between the CYP3A substrate, rilpivirine, and
dolutegravir, an open-label, crossover study was conducted in 16 healthy subjects treated
with dolutegravir 50 mg daily for 5 days, then rilpivirine 25 mg daily for 11 days, followed
by combination treatment with dolutegravir and rilpivirine for 5 days [45]. Consistent with
in vitro findings, co-administration did not significantly impact dolutegravir plasma
exposure with only slight increases of 10–18% for AUC, Cmax, and Ctrough. Similarly,
rilpivirine plasma exposure was not significantly altered by the presence of dolutegravir
(AUC, Cmax, and Ctrough increased by 6–18%).
Due to its ability to induce CYP isozymes and UGT1A1 [46], etravirine, a second
generation NNRTI, has the potential to reduce dolutegravir plasma concentrations. Song et.
al. conducted two open-label, cross-over studies to evaluate the effects of etravirine alone or
in combination with ritonavir-boosted PIs on the pharmacokinetics of dolutegravir in healthy
subjects. In the first study, 15 subjects received 50 mg dolutegravir daily for 5 days,
followed by dolutegravir in combination with 200 mg etravirine twice daily for 14 days. In
the second study, 16 subjects received 50 mg dolutegravir daily for 5 days followed by 14
days of dolutegravir in combination with etravirine 200mg plus lopinavir/ritonavir 400/100
mg twice daily (n=8) or darunavir/ritonavir 600/100 mg twice daily (n=9). Pharmacokinetic
samples were collected on the last day (day 5 and day 14) of each dosing period [47].
Co-administration of etravirine alone led to a 50–88% reduction in dolutegravir AUC, Cmax
and Ctrough. Yet, combining etravirine with boosted PIs attenuated this interaction. It was
shown that etravirine combined with lopinavir/ritonavir slightly increased dolutegravir
AUC, Cmax and Ctrough by 7–26%; while etravirine combined with darunavir/ritonavir only
reduced dolutegravir AUC, Cmax, and Ctrough by 12–37%. Dolutegravir plasma exposure
remained >9 fold above the in vitro, protein adjusted IC90 for the duration of the dosing
interval. The authors concluded that, while dolutegravir should not be administered in an
etravirine containing regimen alone, this combination might be considered without dose
adjustments in a regimen containing lopinavir/ritonavir or darunavir/ritonavir [47].
4.4 Protease Inhibitors
UGT1A1 inhibitors, such as atazanavir have the potential to increase dolutegravir plasma
concentrations. Conversely, ritonavir is a well-known inducer of the UGT1A1 pathway and
thus has the potential to decrease dolutegravir plasma concentrations. A randomized, open-
label, cross-over study was conducted to assess the effect of atazanavir and atazanavir/
ritonavir on the pharmacokinetics of dolutegravir [48]. Twenty-four healthy volunteers
received dolutegravir 30 mg daily for 5 days, followed by co-administration of dolutegravir
and atazanavir 400 mg daily or atazanavir/ritonavir 300/100 mg daily for 14 days. Giving
atazanavir alone increased plasma dolutegravir exposures by 50–180%, whereas giving
atazanavir/ritonavir increased dolutegravir exposures by only 34–121%. This diminished
effect is likely related to ritonavir-mediated UGT1A1 induction with ritonavir attenuating
the inhibitory effect of atazanavir on this pathway. The co-administration of both atazanavir
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and atazanavir/ritonavir with dolutegravir did produce modest increases in dolutegravir
exposure. Yet, no increase in adverse effects was seen, and mean AUC values
(87.4μgml−1h) were still lower than the mean AUC values achieved from a well-tolerated
single dose of dolutegravir 100 mg in phase I studies (131 μgml−1h) [11]. Thus, despite a
modest increase in dolutegravir exposure, it was determined that no dose adjustment for
dolutegravir is necessary when co-administered with atazanavir or atazanavir/ritonavir [48].
Darunavir and lopinavir are well known inhibitors of the CYP3A4 pathway, and therefore,
may increase dolutegravir plasma concentrations. In a randomized, open-label, crossover
study, 30 subjects received 30 mg dolutegravir once daily for 5 days and were then
randomized to receive dolutegravir with lopinavir/ritonavir 400/100 mg twice daily or
darunavir/ritonavir 600/100 mg twice daily for 14 days. Lopinavir/ritonavir did not
significantly affect dolutegravir exposure; whereas darunavir/ritonavir decreased
dolutegravir exposure by 11–38% [49]. However, this reduction was not deemed clinically
significant as the dolutegravir Ctrough was still ~7 fold higher than the in vitro, protein
adjusted IC90 despite using a lower dose (30 mg) of dolutegravir than was assessed in phase
II/III trials.
Tipranavir exhibits a complicated drug interaction profile, as it is both a substrate and an
inducer of CYP3A4, the minor metabolic pathway for dolutegravir [50]. The interaction
potential between dolutegravir and tipranavir/ritonavir was investigated in an open-label,
single-sequence study. Eighteen healthy volunteers received 50 mg of dolutegravir once
daily for 5 days, then 7 days of 500/200 mg of tipranavir/ritonavir twice daily alone,
followed by dolutegravir plus tipranavir/ritonavir combined for 5 days [43,44]. Co-
administration of tipranavir/ritonavir lowered dolutegravir concentrations pharmacokinetic
parameters (AUC, Cmax, and Ctrough) by 59%, 46% and 76% respectively. However,
dolutegravir concentrations remained well above the in vitro, protein adjusted IC90 and still
achieved Ctrough values equivalent to the Ctrough demonstrated by daily 10mg dolutegravir in
the phase II dose-ranging trial (0.29 vs 0.3μg/ml). Consequently, it was concluded that dose
adjustments are not necessary for dolutegravir combined with tipranavir/ritonavir in INSTI-
naive patients [43,44].
The effect of concomitant fosamprenavir/ritonavir on dolutegravir pharmacokinetic profile
has also been evaluated. In 12 healthy adult subjects, fosamprenavir/ritonavir was shown to
decrease dolutegravir AUC, Cmax and Ctrough by 24–50% [51]. Since dolutegravir exposure
at the end of the dosing interval remained 4 fold greater than the in vitro, protein adjusted
IC90 this decrease in exposure was deemed clinically insignificant and standard dolutegravir
dosing may be used when fosamprenavir/ritonavir is combined with dolutegravir.
4.5 Acid-Reducing Agents
All INSTI activity is dependent on binding to magnesium ions located at the catalytic site of
the integrase enzyme to inhibit transfer of the viral DNA strand into the host genome.
Therefore, chelation with therapeutic agents containing metal cations can occur. An open-
label, randomized, crossover study evaluating the effect of co-administration of dolutegravir
with metal cation-containing products, such as antacids and multivitamins (MVIs), was
performed [52]. Sixteen subjects received 50 mg dolutegravir alone, together with a single
oral dose of a One A Day Maximum MVI (Bayer Corporation, Morristown NY, USA), with
a single oral dose of Maalox Advances Maximum Strength Liquid antacid (Novartis,
Parsippany NJ, USA), and 2 h before a single dose of antacid. Expectedly, concurrent
administration of the MVI resulted in modest (33%) reduction of dolutegravir AUC.
Concomitant and staggered antacid administration reduced single-dose dolutegravir
exposure by 74% and 26%, respectively. While concomitant administration of MVI and
staggered administration of antacids did produce a modest reduction in dolutegravir AUC,
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Ctrough values, in both treatment groups Ctrough was still 5–6 fold > in vitro, protein adjusted
IC90. Therefore, it was recommended that dolutegravir should be administered at least 2h
before, or 6 hours after, an antacid and may be given concomitantly with a MVI [52].
An interaction between dolutegravir and proton pump inhibitors (PPI) might occur either
through a change in absorption-limiting solubility caused by altering gastric pH or through a
metabolic interaction via CYP isoenzymes. To evaluate the effect of pH-altering agents on
dolutegravir exposure, 12 healthy subjects received a single 50 mg dose of dolutegravir
under fasted conditions, followed by omeprazole 40 mg once daily for 5 days as part of a
randomized, open-label, crossover study. On day 5, subjects also received a single 50 mg
dose of dolutegravir 2 h after omeprazole administration [52]. Simultaneous administration
of omeprazole resulted in non-significant reduction in dolutegravir exposure, with geometric
least squares mean (GLSM) ratios for AUC, Cmax and C24 ranging from 0.92 to 1.00. Since
co-administration of omeprazole minimally affected dolutegravir plasma exposure,
dolutegravir may provide a clinical alternative to once daily PI containing regimens
(specifically atazanavir/ritonavir) in patients requiring acid-controlling pharmacotherapy
[52].
4.6 Antimycobacterial agents
Rifamycins are commonly used in the treatment of tuberculosis (TB) and present a challenge
in HIV/TB co-infection due to complicated drug interaction profiles. Rifampin is a potent
CYP and UGT pathway inducer, and rifabutin, a CYP3A4 substrate, requires bidirectional
dose adjustments when used with some CYP3A4 inhibitors. To assess the pharmacokinetic
drug interaction potential of rifamycins with dolutegravir, Dooley et. al. conducted an open-
label, fixed-sequence, crossover study [53]. Eleven healthy subjects in Arm 1 received 50
mg of dolutegravir once daily for 7 days, followed by 50 mg of dolutegravir twice daily for
7 days, and then 50 mg of dolutegravir twice daily co-administered with 600 mg of rifampin
once daily for 14 days. Nine healthy subjects in Arm 2 received 50 mg of dolutegravir once
daily for 7 days, followed by 50 mg of dolutegravir once daily together with 300 mg of
rifabutin once daily for 14 days. Pharmacokinetic comparison in Arm 1 demonstrated that
50 mg dolutegravir twice daily administered with rifampin 600 mg daily resulted in only
modestly increased plasma dolutegravir exposure when compared to 50 mg dolutegravir
once daily alone (mean AUC = 33% increase, Ctrough = 22% increase). This indicates that
dolutegravir dosing should be increased to 50 mg twice daily when combined with the
inducer rifampin. Comparison in Arm 2 showed that co-administration of dolutegravir 50
mg daily and rifabutin 300 mg daily resulted in a modest (30%) decrease in dolutegravir
Ctrough which was still 8 fold greater than the in vitro, protein adjusted IC90. Therefore,
rifabutin may provide a better clinical option for the treatment of TB in patients on a
dolutegravir containing regimen, as no dolutegravir dose adjustments are required [53].
4.7 Oral Contraceptives
Although the potential for a drug interaction between dolutegravir and oral hormonal
contraceptives (OCs) is low, a double blind, crossover study was designed to evaluate
potential drug interactions. Sixteen healthy females were randomized to receive once daily
Ortho-Cyclen, containing norgestimate (NGMN) and ethinyl estradiol (EE), from day 1–21
of their menstrual cycle plus either 50 mg dolutegravir twice daily or placebo twice daily for
10 days. Subjects then switched to the alternate treatment for another 10 days [54].
Expectedly, dolutegravir pharmacokinetic parameters were not altered in the presence of
NGMN or EE when dolutegravir to historical controls. Plasma hormonal pharmacokinetic
profiles were also unchanged by the presence of dolutegravir as evidenced by GLSM ratios
of 1.03 and 0.975 for EE and NGMN, respectively. Additionally, administering dolutegravir
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with Ortho-Cyclen had no effect on any pharmacodynamic marker of OC activity (e.g.
luteinizing hormone, follicle stimulating hormone, and progesterone levels) [54].
4.8 Hepatitis agents
Boceprevir and telaprevir are HCV PIs prescribed in combination with pegylated interferon
and ribavirin for the treatment of HCV. Both boceprevir and telaprevir have demonstrated
strong inhibition of CYP3A4/5 metabolic pathways and thus have the potential to increase
plasma dolutegravir exposure through inhibition of its minor metabolic pathway. An open-
label, two-cohort study in healthy adult subjects was conducted to assess the
pharmacokinetics of dolutegravir in the presence of boceprevir and telaprevir [55]. Twenty-
eight subjects received dolutegravir 50 mg once daily for 5 days and were then randomized
to receive dolutegravir in combination with either boceprevir 800 mg three times daily or
telaprevir 750 mg three times daily for 10 days. Co-administration of boceprevir and
dolutegravir increased dolutegravir Ctrough by 8% but had no effect on AUC or Cmax. Co-
administration of telaprevir and dolutegravir resulted in increased dolutegravir plasma
exposures relative to dolutegravir alone as evidenced by 25%, 19%, and 37% increases in
AUC, Cmax, and Ctrough, respectively. Hence, it was concluded that dolutegravir could be
co-administered without dose-adjustment in HIV/HCV co-infected patients receiving HCV
treatment with boceprevir and telaprevir [55].
4.9 Opioid agonists
Methadone is a racemic opioid receptor commonly used for the management of chronic pain
or opioid addiction. Methadone is extensively metabolized by the CYP pathway and
interacts with a number of different therapeutic agents. An open-labeled, crossover study
evaluated the effects of dolutegravir when co-administered with methadone in 12 opioid
dependent subjects receiving individualized doses of daily methadone [54]. Plasma exposure
of both R- and S-Methadone was not significantly altered by dolutegravir with GLSM ratios
for AUC, Cmax, and Ctrough ranging from 0.95 to 1.03. Because study subjects were on
stable methadone therapy prior to enrollment, this study was unable to assess the effects of
methadone on dolutegravir’s pharmacokinetic parameters. Previous in vitro study has found
that methadone only modestly induces UGT1A1 in hepatic microsomes at concentrations
that are higher (10–50 μM) than the mean peak concentrations of methadone treatment
demonstrated by Song et. al. (1.36 μM) [54,56]. Considering that UGT1A1 is dolutegravir’s
primary metabolic pathway, a methadone-mediated drug interaction would be unexpected.
5. Conclusions
Dolutegravir is a second-generation INSTI that preferentially blocks the strand transfer step
during the viral integration process. Dolutegravir’s favorable and predicable
pharmacokinetic profile offers several clinical advantages over currently marketed INSTIs.
The lack of an effect on drug transporters and CYP enzymes is of value for an HIV infected
population requiring poly-pharmacy. Additionally, the drug exposure achieved by once daily
dolutegravir dosing negates the need for a concomitant pharmacokinetic enhancing agent
(such as ritonavir or cobicistat), which also minimizes drug interaction potential.
Dolutegravir also has a favorable safety profile with nausea, headache, and diarrhea being
seen in <20% of patients. Dolutegravir has potent antiretroviral activity in both ARV-naïve
and experienced patients, including those with first generation INSTI resistance mutations.
With its potent activity, tolerability, ease of dosing, and minimal drug interaction profile,
dolutegravir is poised to become one of the key components in the treatment of HIV
infection.
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Figure 1. Dolutegravir chemical structure
[57].
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Mean change from baseline in HIV-1 RNA. BL baseline, C dosage interval, Emax maximum
effect, FU follow-up, IC50 concentration producing 50% inhibition, OD once daily
(reproduced with permission from Min S. et al. Antiviral activity, safety, and
pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-
infected adults. AIDS. 27(4): 673.)
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Figure 3. Efficacy results from phase II and III clinical trials
Proportion of subjects with HIV <50 copies/ml in the SPRING-1, -2 [17, 19], SINGLE [33],
VIKING [18] and VIKING-3 [35] at various weeks post therapy initiation. DTG
dolutegravir, EFV efavirenz, FTC emtricitabine, RAL raltegravir, TDF tenofovir disoproxil
fumarate
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Table 2









VIKINGa Cohort I & II
n=51 (%)
Any event 132 (85) 399 (82) 369 (89) 29 (57)
Nausea 19 (12) 59 (14) 59 (14) NR
Headache 10 (6) 51 (12) 55 (13) NR
Diarrhea 12 (8) 47 (11) 72 (17) 3 (6)
Nasopharyngitis NR 46 (11) 62 (15) NR
Dizziness 5 (3) 23 (6) 37 (9) NR
Sleep disturbances (insomnia,
abnormal dreams etc.)
3 (2) 21 (5) 94 (23) 3 (6)
Fatigue 5 (3) 20 (5) 54 (13) NR
Upper respiratory tract
infection
NR 26 (6) 36 (9) NR
Pyrexia NR 20 (5) NR NR
Depression NR 21 (5) 23 (6) NR
Pharyngitis NR 14 (3) NR NR
Bronchitis NR 19 (5) NR 3 (6)
Anxiety NR 14 (3) 14 (3) NR
Cough NR NR NR 3 (6)
Rash 2 (1) NR 14 (3) NR
Asthenia 4 (3) NR NR NR
DTG, dolutegravir; NR, not reported
a
Only ≥ Grade 2 adverse events reported
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Table 3
Summary of dolutegravir drug interaction data.
Interacting drug class Interacting drug Effect on integrase inhibitor or interactingdrug concentration Maintain standard dosing
Antiretrovirals
NRTIs TDF No significant effect observed Yes
NNRTIs
EFV








DTG AUC, Cmax, and Cmin decreased 71, 52,
and 88%, respectively
Do not co-administer DTG and ETR
alone
ETR/DRV/r
ETR/DRV/r administration results in 25, 11.8,
and 37.1% decreases in DTG AUC, Cmax, and
Cmin, respectively
Administer DTG and ETR only if
DRV/r also included in the regimen
ETR/LPV/r
ETR/LPV/r administration results in 11, 7, and
28% increases in DTG AUC, Cmax, and Cmin,
respectively
Administer DTG and ETR only if
LPV/r also included in the regimen
PIs
DRV/r
DRV/r led to DTG AUC, Cmax, and Cmin
decreases of 22, 11, and 38%, respectively
Yes
ATV




DTG AUC, Cmax, and Cmin increased 62, 34,
and 121%, respectively
Yes
LPV/r No significant effect observed Yes
FPV/r








PPIs Omeprazole No significant effect observed Yes
Antacids Maalox AdvancedMaximum Strength
DTG AUC, Cmax, and Cmin decreased 74, 72,
and 74%, respectively
Administer antacids 2 h after or 6 h
before DTG dosing
Over The Counter Agents




DTG AUC and Cmin increased 33 and 22%
(DTG 50mg twice daily plus RIF 600 mg once
daily versus DTG 50 mg daily)
Increase DTG dosing frequency to 50
mg twice daily
RBT
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Interacting drug class Interacting drug Effect on integrase inhibitor or interactingdrug concentration Maintain standard dosing
Ortho-Cyclen No significant effect observed Yes
Anti-Hepatitis C Virus Agents
NS3A4 PIs
BCV
BCV increased DTG Ctrough 8% but had no
effect on AUC or Cmax
Yes
TVR
DTG AUC, Cmax, and Ctrough increased 25%,
19%, and 37%, respectively
Yes
Opioid Agonist
Methadone Unable to assess the effects of methadone onDTG pharmacokinetic parameters No dosing recommendation
ATV, Atazanavir; AUC, area under the concentration time curve; BCV, Boceprevir; Cmax, maximum plasma concentration; Cmin, minimum
plasma concentration; Ctrough, trough plasma concentration; DRV, Darunavir; DTG, Dolutegravir; EFV, Efavirenz; ETR, Etravirine; EVG,
Elvitegravir; FPV, fosamprenavir; LPV, Lopinavir; MVI, Multivitamins; NNRTI, Non-nucleoside reverse transcriptase inhibitor; NRTI,
Nucleoside reverse transcriptase inhibitor; PI, Protease Inhibitor; PPI, Proton pump inhibitor; RPV, Rilpivirine; RTV, Ritonavir; RBT, Rifabutin;
RIF, Rifampin; TDF, tenofovir disoproxil fumarate; TVR, Telaprevir
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